Herpes Simplex - Drug Pipeline Analysis and Market Forecasts to 2016

04 Jun 2010 • by Natalie Aster

GlobalData, the industry analysis specialist’s new report, “Herpes Simplex - Drug Pipeline Analysis and Market Forecasts to 2016” is an essential source of information and analysis on the global Herpes Simplex market. The report identifies the key trends shaping and driving the dynamism in the global Herpes Simplex market. The report also provides insight into the prevalent competitive landscape and the emerging players expected to bring a significant shift in the positioning of the existing market leaders. Most importantly, the report provides valuable insight into the pipeline products within the global Herpes Simplex market.

The Herpes Simplex Therapeutics Market is Forecast to Show Modest Growth until 2016

The global herpes simplex therapeutics market was worth approximately $2.9 billion in 2009. In 2001 the market was valued at approximately $1 billion and it grew at an approximate Compound Annual Growth Rate (CAGR) of 14% from 2001 to 2009. The global Herpes Simplex therapeutics market is expected to reach $6 billion by 2016, growing at a CAGR of 11.1%. The primary factor contributing to the increase in revenues over the forecast period is the increase in disease incidence. Presently, the therapeutic regimen for herpes simplex is dominated by a range of DNA polymerase inhibitors which include Zovirax, Famvir, Valtrex, Denavir and OTC (Over The Counter) products such as Abreva and Aviralex. This market is a significantly genericized market, with many brands across the seven geographies covered. Tablet prices range between $1 and $3 depending on the brand. The average annual cost of therapy for herpes simplex therapeutics ranges between $725 and $2,050 based on the treatment regimen (reduction or suppression therapy).

The Herpes Simplex Therapeutics Market Pipeline is Relatively Weak

The market has limited scope for growth due to the presence of generic products and the lack of innovation with respect to better efficacy and safety drug profiles. The herpes simplex developmental pipeline is weak, with only 34 molecules in the various phases of clinical development. There are five first-in-class molecules across all the phases of development. Overall, there are eight molecules whose mechanisms of action are not known or have not been disclosed by the parent company. Phase III contains no first-in-class molecules but has five generic candidates. Phase II contains only one first-in-class molecule, which is a helicase-primase inhibitor.

The Herpes Simplex Therapeutics Market Has Low Unmet Needs to be Addressed

The herpes simplex therapeutics market has moderate to low unmet needs in terms of both efficacy and safety. The low unmet needs imply that the market is well served by the current product options and that there is not much scope available for new entrants to capture value from underserved segments. The efficacy of the present therapeutics ranges from moderate to strong, with drugs such as Zovirax having significantly strong efficacy profiles. The therapeutic interventions for herpes simplex are limited to oral formulations. Since the market is genericized, there are many available brands and prices are low.

Safety is a moderate concern for this market. The occurrence of headaches and nausea is prevalent among the patient population and safer drugs are needed. Apart from these complications, dizziness and abdominal pain also make up a major share of the side effects for the present therapeutics drugs. The need for safer drugs, especially with respect to the target population of patients between the ages of 18 and 50 years, is the primary unmet need for the herpes simplex therapeutics market.

The Reluctance to Seek Treatment is a Major Barrier to the Herpes Simplex Therapeutics Market

HSV infections are a significant health issue with a considerable social and economic impact. Patients’ quality of life (QOL) can be significantly impacted by this disorder as psychological, occupational, social domestic, physical, and sexual functioning are all affected. Even though there are a significant number of therapeutic options in the market, Herpes Simplex remains under-recognized and untreated due to patients’ embarrassment and reluctance to seek medical help. This lack of awareness and reluctance to seek treatment affects the Herpes Simplex therapeutics market considerably.

About GlobalData

GlobalData is an industry analysis specialist company providing business information products and services.

Our highly qualified team of Analysts, Researchers, and Solution Consultants use proprietary data sources and various tools and techniques to gather, analyze and represent the latest and the most reliable information essential for businesses to sustain a competitive edge.